You can access any of the podium or poster presentations’ abstracts by searching for it below.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Fragment-based Discovery of Allosteric Modulators on Metabotropic Glutamate Receptor 5
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-007-Monday
- By: BIAN, Yuemin (University of Pittsburgh, School of Pharmacy, Pittsburgh, United States)
- Co-author(s): Yuemin Bian: School of Pharmacy, University of Pittsburgh, Pittsburgh, United States;Drug Discovery Institute, University of Pittsburgh, Pittsburgh, United States;NIH National Center of Excellence for Computational Drug Abuse Research, National Institution of Health, Pittsburgh, United States
Zhiwei Feng: School of Pharmacy, University of Pittsburgh, Pittsburgh, United States;Drug Discovery Institute, University of Pittsburgh, Pittsburgh, United States;NIH National Center of Excellence for Computational Drug Abuse Research, National Institution of Health, Pittsburgh, United States
Peng Yang: School of Pharmacy, University of Pittsburgh, Pittsburgh, United States;Drug Discovery Institute, University of Pittsburgh, Pittsburgh, United States;NIH National Center of Excellence for Computational Drug Abuse Research, National Institution of Health, Pittsburgh, United States
Xiang-Qun Xie: School of Pharmacy, University of Pittsburgh, Pittsburgh, United States;NIH National Center of Excellence for Computational Drug Abuse Research, National Institution of Health, Pittsburgh, United States;Drug Discovery Institute, University of Pittsburgh, Pittsburgh, United States;Department of Computational Biology and Structural Biology, University of Pittsburgh, Pittsburgh, United States - Abstract:
Backgrounds
Allosteric modulators exhibit significant advantages against the corresponding orthosteric ligands, including better physicochemical properties, improved selectivity, and reduced risk of over-sensitization towards their receptors. mGlu5, a member of class C GPCRs, has been considered a promising therapeutic target for treating many CNS.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 2 July 2026